REG - Creo Medical Group - Director/PDMR Share Dealing

Creo MedicalAnnouncement

Tue 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250812:nRSL0529Va&default-theme=true

RNS Number : 0529V  Creo Medical Group PLC  12 August 2025

 

LEI: 213800H188ZDCWWXFA21

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Director/PDMR Share Dealing

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, was informed on 8 August 2025 that Richard Rees, Chief
Financial Officer of the Company, passed the control of 362,408 ordinary
shares of 0.1 pence each in the Company ("Ordinary Shares") to three of his
children who are now aged eighteen or older.

 

Consequently, Mr Rees's total beneficial interest in the Company has reduced
by 362,408 Ordinary Shares to 2,707,555 (1) Ordinary Shares, representing
approximately 0.66% of the Company's issued share capital.

 

(1) Including shares held by certain other PCAs of Mr Rees

 

For further information please contact:

 

 Creo Medical Group plc                                                      www.creomedical.com
                                                                             (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                           Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Broker and Financial Adviser)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Sher Shah

 Walbrook PR Ltd                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings      Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Richard John Rees

 2   Reason for the notification
 a)  Position/status                                              Chief Finance Officer

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc

 b)  LEI                                                          213800H188ZDCWWXFA21

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification code                                          GB00BZ1BLL44

 b)  Nature of the transaction                                    Transfer of Ordinary Shares

 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     Nil                                                                                       167,038
 d)  Aggregated information

     Aggregated volume                                            167,038
     Price                                                        Nil

 e)  Date of the transaction                                      8 August 2025

 f)  Place of the transaction                                     London Stock Exchange

 

 

 

 

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Richard John Rees

 2   Reason for the notification
 a)  Position/status                                              Chief Finance Officer

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc

 b)  LEI                                                          213800H188ZDCWWXFA21

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification code                                          GB00BZ1BLL44

 b)  Nature of the transaction                                    Transfer of Ordinary Shares

 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     Nil                                                                                       121,086

 d)  Aggregated information

     Aggregated volume                                            121,086
     Price                                                        Nil

 e)  Date of the transaction                                      8 August 2025

 f)  Place of the transaction                                     London Stock Exchange

 

 

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Richard John Rees

 2   Reason for the notification
 a)  Position/status                                              Chief Finance Officer

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Creo Medical Group plc

 b)  LEI                                                          213800H188ZDCWWXFA21

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification code                                          GB00BZ1BLL44

 b)  Nature of the transaction                                    Transfer of Ordinary Shares

 c)  Price(s) and volumes(s)                                      Price(s)                     Volume(s)
     Nil                                                                                       74,284
 d)  Aggregated information

     Aggregated volume                                            74,284
     Price                                                        Nil

 e)  Date of the transaction                                      8 August 2025

 f)  Place of the transaction                                     London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHELLFFEVLEBBZ